[
  {
    "id": 1,
    "cancerType": "Breast Cancer",
    "histology": "Ductal",
    "biomarkers": [
      "HER2+",
      "ER+"
    ],
    "treatmentIntent": "Curative",
    "lineOfTreatment": "1st Line",
    "treatmentProtocol": "TCH (Docetaxel + Carboplatin + Trastuzumab)",
    "evidenceReference": "Category 1",
    "nccnReference": "BREAST-4",
    "conflictingBiomarkers": null,
    "requiredStage": [
      "II",
      "III"
    ],
    "confidenceScore": "0.92",
    "isActive": true,
    "createdAt": "2025-06-30T11:14:00.837Z",
    "updatedAt": "2025-06-30T11:14:00.837Z"
  },
  {
    "id": 2,
    "cancerType": "Breast Cancer",
    "histology": "Ductal",
    "biomarkers": [
      "HER2+",
      "ER-"
    ],
    "treatmentIntent": "Curative",
    "lineOfTreatment": "1st Line",
    "treatmentProtocol": "AC-TH (Doxorubicin + Cyclophosphamide â†’ Docetaxel + Trastuzumab)",
    "evidenceReference": "Category 1",
    "nccnReference": "BREAST-4",
    "conflictingBiomarkers": null,
    "requiredStage": [
      "II",
      "III"
    ],
    "confidenceScore": "0.90",
    "isActive": true,
    "createdAt": "2025-06-30T11:14:00.837Z",
    "updatedAt": "2025-06-30T11:14:00.837Z"
  },
  {
    "id": 3,
    "cancerType": "Lung Cancer (NSCLC)",
    "histology": "Adenocarcinoma",
    "biomarkers": [
      "PD-L1+"
    ],
    "treatmentIntent": "Palliative",
    "lineOfTreatment": "1st Line",
    "treatmentProtocol": "Pembrolizumab Monotherapy",
    "evidenceReference": "Category 1",
    "nccnReference": "NSCL-8",
    "conflictingBiomarkers": null,
    "requiredStage": [
      "IV"
    ],
    "confidenceScore": "0.88",
    "isActive": true,
    "createdAt": "2025-06-30T11:14:00.837Z",
    "updatedAt": "2025-06-30T11:14:00.837Z"
  },
  {
    "id": 4,
    "cancerType": "Lung Cancer (NSCLC)",
    "histology": "Adenocarcinoma",
    "biomarkers": [
      "EGFR+"
    ],
    "treatmentIntent": "Palliative",
    "lineOfTreatment": "1st Line",
    "treatmentProtocol": "Osimertinib",
    "evidenceReference": "Category 1",
    "nccnReference": "NSCL-9",
    "conflictingBiomarkers": null,
    "requiredStage": [
      "IV"
    ],
    "confidenceScore": "0.95",
    "isActive": true,
    "createdAt": "2025-06-30T11:14:00.837Z",
    "updatedAt": "2025-06-30T11:14:00.837Z"
  },
  {
    "id": 5,
    "cancerType": "Colorectal Cancer",
    "histology": "Adenocarcinoma",
    "biomarkers": [
      "MSI-H"
    ],
    "treatmentIntent": "Palliative",
    "lineOfTreatment": "1st Line",
    "treatmentProtocol": "Pembrolizumab + Chemotherapy",
    "evidenceReference": "Category 2A",
    "nccnReference": "COLON-C",
    "conflictingBiomarkers": null,
    "requiredStage": [
      "IV"
    ],
    "confidenceScore": "0.85",
    "isActive": true,
    "createdAt": "2025-06-30T11:14:00.837Z",
    "updatedAt": "2025-06-30T11:14:00.837Z"
  },
  {
    "id": 6,
    "cancerType": "Colorectal Cancer",
    "histology": "Adenocarcinoma",
    "biomarkers": [
      "KRAS+",
      "MSS"
    ],
    "treatmentIntent": "Palliative",
    "lineOfTreatment": "1st Line",
    "treatmentProtocol": "FOLFOX + Bevacizumab",
    "evidenceReference": "Category 1",
    "nccnReference": "COLON-C",
    "conflictingBiomarkers": null,
    "requiredStage": [
      "IV"
    ],
    "confidenceScore": "0.87",
    "isActive": true,
    "createdAt": "2025-06-30T11:14:00.837Z",
    "updatedAt": "2025-06-30T11:14:00.837Z"
  },
  {
    "id": 7,
    "cancerType": "Lung Cancer (SCLC)",
    "histology": "Small Cell",
    "biomarkers": [],
    "treatmentIntent": "Curative",
    "lineOfTreatment": "1st Line",
    "treatmentProtocol": "Cisplatin + Etoposide + Concurrent RT",
    "evidenceReference": "Category 1",
    "nccnReference": "SCLC-4",
    "conflictingBiomarkers": null,
    "requiredStage": [
      "III"
    ],
    "confidenceScore": "0.90",
    "isActive": true,
    "createdAt": "2025-06-30T11:14:00.837Z",
    "updatedAt": "2025-06-30T11:14:00.837Z"
  },
  {
    "id": 8,
    "cancerType": "Lung Cancer (SCLC)",
    "histology": "Small Cell",
    "biomarkers": [],
    "treatmentIntent": "Palliative",
    "lineOfTreatment": "1st Line",
    "treatmentProtocol": "Carboplatin + Etoposide + Atezolizumab",
    "evidenceReference": "Category 1",
    "nccnReference": "SCLC-5",
    "conflictingBiomarkers": null,
    "requiredStage": [
      "IV"
    ],
    "confidenceScore": "0.88",
    "isActive": true,
    "createdAt": "2025-06-30T11:14:00.837Z",
    "updatedAt": "2025-06-30T11:14:00.837Z"
  }
]